Worse Renal Presentation and Prognosis in Initial-Onset Lupus Nephritis than Early-Onset Lupus Nephritis

Purpose To compare the clinical characteristics and renal outcomes between patients who initially had lupus nephritis (LN) at the onset of systemic lupus erythematosus (SLE) (initial-onset LN) and those who developed LN within 5 years after SLE onset (early-onset LN). Materials and Methods SLE patients with biopsy-proven LN were retrospectively reviewed. The clinical parameters and renal outcomes were compared between initial-onset and early-onset LN groups. We used Cox regression analysis to estimate risk of worse renal outcomes according to the onset time of LN. Results Of all 136 LN patients, 92 (67.6%) and 44 (32.4%) patients were classified into the initial-onset and early-onset LN groups, respectively. The initial-onset LN group had higher prevalences of class IV LN (54.3% vs. 34.1%, p=0.027), impaired renal function (34.8% vs. 11.4%, p=0.004), microscopic hematuria (73.9% vs. 54.5%, p=0.024), and higher urine protein/creatinine ratio [4626.1 (2180.0–6788.3) mg/g vs. 2410.0 (1265.0–5168.5) mg/g, p=0.006] at LN diagnosis. Renal relapse (46.3% vs. 25.7%, p=0.039) and progression to chronic kidney disease (CKD) or end-stage renal disease (ESRD) were more common (24.4% vs. 8.3%, p=0.042) in the initial-onset LN group. In Cox regression analysis, the initial-onset LN group had higher risks of renal relapse [adjusted hazard ratio (HR) 3.56, 95% confidence interval (CI) 1.51–8.35, p=0.004] and progression to CKD or ESRD (adjusted HR 4.57, 95% CI 1.03–20.17, p=0.045), compared with the early-onset LN group. Conclusion Patients with LN at SLE onset may have more severe renal presentations and experience worse renal outcomes than those who develop LN within 5 years.

[1]  K. Fujio,et al.  Delayed lupus nephritis in the course of systemic lupus erythematosus is associated with a poorer treatment response: a multicentre, retrospective cohort study in Japan , 2019, Lupus.

[2]  Ming-hui Zhao,et al.  Redefining lupus nephritis: clinical implications of pathophysiologic subtypes , 2017, Nature Reviews Nephrology.

[3]  J. Andreu,et al.  Characterization of Patients With Lupus Nephritis Included in a Large Cohort From the Spanish Society of Rheumatology Registry of Patients With Systemic Lupus Erythematosus (RELESSER) , 2016, Medicine.

[4]  Tasnim F. Imran,et al.  Lupus nephritis: an update , 2016, Clinical and Experimental Nephrology.

[5]  D. D'cruz,et al.  Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis , 2015, Annals of the rheumatic diseases.

[6]  Harold I Feldman,et al.  KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  Caroline Gordon,et al.  Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis , 2012, Annals of the rheumatic diseases.

[8]  D. Isenberg,et al.  Assessment of a lupus nephritis cohort over a 30-year period. , 2011, Rheumatology.

[9]  J. Anaya,et al.  Lupus Nephritis in Colombians: Contrasts and Comparisons with Other Populations , 2011, Clinical reviews in allergy & immunology.

[10]  Su-xia Wang,et al.  Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system. , 2010, Kidney international.

[11]  D. Gipson,et al.  Predictors of relapse and end stage kidney disease in proliferative lupus nephritis: focus on children, adolescents, and young adults. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[12]  T. Mizoue,et al.  Time of initial appearance of renal symptoms in the course of systemic lupus erythematosus as a prognostic factor for lupus nephritis , 2009, Modern rheumatology.

[13]  J. Anaya,et al.  Delayed lupus nephritis , 2008, Annals of the rheumatic diseases.

[14]  L. Pasquier,et al.  Orphanet Journal of Rare Diseases , 2006 .

[15]  C. Mok.  Prognostic factors in lupus nephritis , 2005, Lupus.

[16]  Lee Hebert,et al.  The classification of glomerulonephritis in systemic lupus erythematosus revisited. , 2004, Kidney international.

[17]  G. Hughes,et al.  Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis , 2003, Annals of the rheumatic diseases.

[18]  Y. Levy,et al.  Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. , 2002, Arthritis and rheumatism.

[19]  D. Gladman,et al.  Systemic lupus erythematosus disease activity index 2000. , 2002, The Journal of rheumatology.

[20]  T. Chan,et al.  Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis , 2000 .

[21]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[22]  P H Plotz,et al.  Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. , 1986, The New England journal of medicine.

[23]  A D GUNN,et al.  Case of Anaphylaxis after Anaesthesia , 1943, British medical journal.

[24]  G. Rogers,et al.  Prognostic factors. , 2002, Dermatologic clinics.

[25]  C. Lau,et al.  Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. , 2000, The New England journal of medicine.